To investigate the distribution of thyroid-stimulating antibody (TSAb) activity between IgG subclasses, sera from 11 patients with Graves disease (including the National Institute of Biological Standards and Control (NIBSC) Research Standard, long acting thyroid stimulator-B) were fractionated by chromatography on affinity columns of monoclonal IgG subclass antibodies or protein A to deplete all but a single subclass. The resulting fractions were 98% or more pure for a single subclass. In all 11 patients, TSAb activity appeared to be confined to the IgG, fraction as determined by cAMP production on addition of the fractions to the FRTL-5 rat thyroid cell line. In all of eight specimens from seven patients so tested, the whole serum activity was recovered in the IgG, fraction, after adjusting for the recovery of the isotype from the column. TSAb activity in one serum comprised both lambda and kappa light chains but was IgG1 restricted. This IgG subclass restriction was not found when the same fractions were tested for thyroglobulin, microsomal/thyroid peroxidase, or tetanus toxoid antibody activity. Together with previous results showing marked restriction of both light chain usage and isoelectric point of TSAb, these results support the idea that Graves' disease may be the result of an oligo-or possibly monoclonal response at the B cell level. (J. Clin. Invest. 1990. 86:723-727.)

Studies were conducted to determine whether thyroid-stimulating hormone (TSH; thyrotropin), a hormone known to increase cytosol concentrations of cyclic AMP, also stimulates the formation of inositol phosphates in thyroid cells. TSH and noradrenaline both stimulated [3H]inositol phosphate formation in a concentration-dependent manner in the rat thyroid cell line, FRTL-5 cells, which had been prelabelled with [3H]inositol. The threshold concentration of TSH required to stimulate inositol phosphate formation was more than 20 munits/ml, which is approx. 10(3)-fold greater than that required for cyclic AMP accumulation and growth in these cells. We also demonstrate that membranes prepared from FRTL-5 cells possess a guanine nucleotide-activatable polyphosphoinositide phosphodiesterase, which suggests that activation of inositide metabolism in these cells may be coupled to receptors by the G-protein, Gp. Our findings suggest that two second-messenger systems exist to mediate the action of TSH in the thyroid.

A bioassay system named ESTA (eluted stain assay) has been developed to measure hormones and antibodies which mimic their action. It is derived from approaches used for cytochemical bioassays. Unlike the latter which use tissue segments or sections, ESTA is based upon uniform microcultures of target cells maintained in microtitre plates. Direct elution of the cytochemical stain from these microcultures into the wells of the microtitre plates permits rapid quantification with a microtitre plate reader. We describe ESTA systems for GH, prolactin, thyroid stimulators and human chorionic gonadotrophin which utilize the reduction of a tetrazolium salt to a formazan by intracellular dehydrogenase as the cytochemical system. These provide examples of ESTA systems in which the assay signal depends solely upon an increase in cell number in response to the hormone, or in which there is additional enzymic amplification.

Monoclonal antibodies 208F7 and 307H6, derived from Graves' lymphocytes, were previously shown to stimulate thyroid function. We characterized these antibodies in the ultrasensitive cytochemical bioassay for thyroid stimulators. Bell-shaped dose-response curves were obtained for both antibodies, confirming their actions as thyroid stimulators; 307H6 was 10(7) times more potent than 208F7, and the ascending limb of the response curve to 307H6 was not significantly different from that of a reference preparation of thyroid-stimulating antibodies, namely LATS-B. Stimulation by both 208F7 and 307H6 was inhibited by antihuman, but not antimouse, immunoglobulin. Stimulation by 208F7, but not 307H6, was inhibited by 11E8 (a monoclonal antibody raised against the TSH receptor), which is a relatively potent inhibitor of TSH, but not thyroid-stimulating antibodies. These findings together with previous observations on the interactions of 208F7 and 307H6 with thyroid cells in both the presence and absence of TSH and of 208F7 and 307H6 with solubilized thyroid membrane components are summarized in a model relating the appropriate epitopic regions of the TSH receptor.

The time course of response of thyroid sections in the cytochemical bioassay to either TSH or thyroid-stimulating antibodies is bell shaped. The maximal staining for lysosomal naphthylamidase activity achieved was found to be the same regardless of the dose of stimulator applied; however, the rate at which the maximum was attained was dose dependent. Sections exposed to 10(-1) mU/liter TSH showed a maximal response at 120 sec, and those exposed to 10(-3) mU/liter TSH showed a maximal response at 210 sec. A similar dose-time effect was seen with immunoglobulin G from a thyrotoxic patient. Thus, by selecting a specific exposure time, a dose-response curve to the stimulator was obtained. A dose-response curve to a range of concentrations from 10(-4)-10(-1) mU/liter TSH was obtained by exposing sections to the hormone for 90 sec. TSH (10(-3) mU/liter) produced a response significantly different (P less than 0.0025) from the control. However, 10(-5) mU/liter TSH produced a response significantly different (P less than 0.0025) from the control after an exposure time of 180 sec, and the range of the dose-response curve at this exposure time was 10(-6)-10(-3) mU/liter TSH. Each point on these two dose-response curves was determined in quintuplicate, and precision profiles were constructed. The assay performed at 90 sec had a lower relative precision of 30% at a dose of 10(-1) mU/liter TSH, and at 180 sec, the best lower relative precision achieved was 80%. Thus, the sensitivity of the assay was improved by increasing the exposure time of the sections to TSH, but with a resultant loss of relative precision.